Colon cancer can be hereditary, but most cases are not. About 75% of colorectal cancers are sporadic, meaning they develop in people with no family history or inherited genetic cause. The remaining 25% or so involve some hereditary component, ranging from well-defined genetic syndromes to a vaguer pattern of cancer clustering in families. Only 5% to 6% of all colorectal cancers trace back to a specific, identifiable gene mutation passed from parent to child.
That said, having a family history of colon cancer meaningfully increases your risk even when no specific gene mutation is involved. Understanding where you fall on this spectrum changes when you should start screening and how aggressively you should monitor your health.
The Three Categories of Colorectal Cancer Risk
Colorectal cancer falls into three broad groups. Sporadic cases, which make up roughly three-quarters of all diagnoses, arise from gene changes that accumulate over a person’s lifetime due to aging, diet, lifestyle, or random chance. These mutations aren’t inherited and don’t run in families.
The second group, accounting for 10% to 30% of cases, is called familial colorectal cancer. These families have more colon cancer than expected, but genetic testing doesn’t turn up a known syndrome. The excess risk likely comes from a combination of shared genes with small individual effects, shared environmental exposures, and shared habits like diet. If you have one first-degree relative (parent, sibling, or child) diagnosed with colorectal cancer, your own risk roughly doubles compared to someone with no family history.
The third and smallest group, around 5% to 6% of all cases, involves clearly inherited genetic syndromes where a single gene mutation dramatically raises cancer risk. Lynch syndrome and familial adenomatous polyposis are the most common of these.
Lynch Syndrome: The Most Common Inherited Cause
Lynch syndrome is the single biggest contributor to hereditary colorectal cancer. It’s caused by mutations in genes responsible for repairing DNA copying errors. When these repair genes don’t work properly, mistakes pile up in your DNA every time cells divide, and some of those mistakes eventually trigger cancer.
The lifetime risk of developing colorectal cancer with Lynch syndrome depends on which gene is affected. People with mutations in the two most commonly involved genes face a 40% to 70% chance of developing colorectal cancer by age 70. Mutations in two less commonly affected genes carry lower but still significant risks of 10% to 22% and 15% to 20%, respectively.
Lynch syndrome doesn’t just raise the risk of colon cancer. Women with the condition face a 15% to 44% lifetime risk of endometrial cancer and a 4% to 11% risk of ovarian cancer, depending on the specific gene involved. There are also elevated risks for cancers of the stomach, urinary tract, small intestine, pancreas, and brain, though these are each in the single digits.
A related condition called Familial Colorectal Cancer Type X looks similar on the surface. Families meet the same clinical patterns as Lynch syndrome, with multiple relatives affected across generations, but genetic testing shows no mutations in the DNA repair genes. These families tend to develop cancer later in life and have a lower risk of cancers outside the colon.
Familial Adenomatous Polyposis
FAP is rarer than Lynch syndrome but more aggressive. People with classic FAP develop hundreds to thousands of polyps in the colon, sometimes starting in childhood. Without preventive surgery to remove the colon, at least 90% of affected individuals will develop colorectal cancer by age 50.
A milder version, called attenuated FAP, produces fewer polyps (an average of 30) that appear later, typically in early to mid-adulthood. Even in this milder form, the lifetime colorectal cancer risk is about 70%, with cancer usually developing around age 55. FAP follows a dominant inheritance pattern, meaning a child of someone with the condition has a 50% chance of inheriting it.
MUTYH-Associated Polyposis
This condition is inherited differently from most hereditary cancer syndromes. It follows a recessive pattern, meaning you need to inherit a defective copy of the gene from both parents to be affected. Each parent carries one altered copy without necessarily developing cancer themselves. Without monitoring and early intervention, people with this condition face an 80% to 90% lifetime risk of colorectal cancer. It can also raise the risk of cancers in the duodenum, breast, ovary, endometrium, and bladder, though the exact degree of increased risk for those sites is still unclear.
Signs That Cancer in Your Family May Be Hereditary
Not every family with colon cancer has a genetic syndrome. But certain patterns raise the probability enough that genetic evaluation is recommended. Clinicians look for features like colorectal or endometrial cancer diagnosed before age 50, multiple family members with colorectal cancer (especially across two or more generations), a single person developing more than one colorectal cancer, or the presence of other Lynch-associated cancers in the family tree.
On the polyp side, finding more than 10 adenomatous polyps during a colonoscopy, or finding hamartomatous polyps (a distinct type), should prompt further investigation. Finding more than 20 adenomas is a strong signal for referral to a genetics specialist. Guidelines generally recommend genetic evaluation for anyone whose personal and family history gives them a 5% or greater predicted chance of carrying Lynch syndrome.
When to Start Screening With a Family History
Standard colorectal cancer screening starts at age 45 for people at average risk. But if you have a family history, the timeline moves up. The US Multi-Society Task Force recommends starting screening at age 40, or 10 years before the age at which your family member was diagnosed, whichever comes first. So if your parent was diagnosed at 42, you’d start at 32.
For people with confirmed Lynch syndrome, colonoscopy screening starts even earlier, between ages 20 and 25 (or two to five years before the youngest cancer diagnosis in the family). These colonoscopies happen every one to two years rather than the typical every-ten-year schedule for average-risk adults. Surveillance for other Lynch-associated cancers begins in the early 30s, including upper endoscopy every three to five years for stomach cancer and annual screening for urinary tract cancers.
People with FAP may need colonoscopies starting in their teens, given that polyps can appear in childhood and cancer risk escalates quickly.
Aspirin for Prevention in Lynch Syndrome
One of the more promising findings for people with Lynch syndrome is that regular aspirin use appears to substantially reduce colorectal cancer risk. A major clinical trial followed over 860 Lynch syndrome carriers and found, after 20 years of follow-up, that those assigned to take aspirin had a 35% reduction in colorectal cancer risk. Among participants who took aspirin consistently for at least two years, the reduction was even larger: 59%. The benefit was particularly pronounced in people who were overweight.
Several international guidelines now recommend aspirin for Lynch syndrome carriers, typically starting at age 25 and continuing for at least two to two and a half years. The recommended dose varies by guideline, generally ranging from 75 to 600 milligrams daily, with some groups suggesting higher doses for people who are overweight. The decision is best made on an individual basis, weighing the cancer prevention benefit against aspirin’s well-known risks, particularly gastrointestinal bleeding.
What Genetic Testing Involves
If your family history raises concern, genetic testing typically starts with a blood or saliva sample that screens for mutations in the relevant genes. In some cases, testing begins with tumor tissue from a family member who already had cancer, since certain features of the tumor itself can indicate whether Lynch syndrome or another hereditary condition is likely.
A positive result doesn’t mean you will get cancer. It means your risk is elevated and you need a more aggressive screening and prevention plan. A negative result in someone from a high-risk family can be reassuring, but it doesn’t eliminate the need for earlier-than-average screening if the family pattern is strong, since not all hereditary risk factors have been identified yet. If you have three or more close relatives with colorectal cancer spanning at least two generations, with at least one diagnosed before 50, genetic evaluation is worth pursuing regardless of your current age or health.